Gary Peters is not dominating the news cycle right now. Zero Google News hits in the last 24 hours. But Bluesky has found him anyway, and the conversation isn't flattering: he's apparently been working the phones asking Mallory McMorrow to stand down in the Michigan Senate primary so the field doesn't fracture and hand the seat to Abdul El-Sayed's rising campaign. Meanwhile, on April 23, Peters was busy doing something else entirely. He sold Corteva, bought PepsiCo, and picked up a small position in J.M. Smucker. All on the same day. Peters sits on the Senate Appropriations subcommittee covering Agriculture, Rural Development, and the FDA. He also sits on Commerce. The filings are public. The committee assignments are public. The calendar is public.
The Primary Mess, First
The Bluesky chatter paints a picture of a senator who is simultaneously trying to exit his seat gracefully and control who replaces him. Peters announced he wouldn't seek re-election, which opened the door. McMorrow jumped in. El-Sayed jumped in. Peters, per the social conversation, would prefer McMorrow to step aside.
The math of a three-way primary is not complicated. A split moderate-to-progressive vote is the best available outcome for the candidate running furthest left. Peters apparently understands this. Whether his phone calls constitute kingmaking or just good old-fashioned Michigan Democratic Party table-clearing is a matter of interpretation.
What it is, unambiguously, is a senator spending his lame-duck months with his hand on the scale of his own succession. That's the news peg. Now here's what Blind Trust uniquely knows.
April 23: Three Trades, One Day, Two Flags
On April 23, 2026, Peters filed three disclosed transactions. Per his full disclosure record on Blind Trust:
- Sold Corteva (CTVA), $15K-$50K range
- Bought PepsiCo (PEP), $15K-$50K range
- Bought J.M. Smucker (SJM), $1K-$15K range
Corteva is an agricultural chemicals and seed company. PepsiCo is one of the largest food and beverage companies on earth. J.M. Smucker makes jams, Folgers coffee, Jif peanut butter, and Milk-Bone dog treats, which is a portfolio that describes either a grocery list or an investment thesis.
Peters's Appropriations subcommittee covers agriculture and the FDA. His Commerce Committee assignments include Science, Manufacturing, and Competitiveness. The overlap between "senator who oversees agricultural inputs and food regulation" and "investor rotating out of an ag-chemicals company and into consumer food staples" is not zero.
The trade data flags both the Corteva sale and the PepsiCo purchase as committee overlap trades. The Corteva overlap is tagged to Agriculture. The PepsiCo overlap is tagged to Food and Beverage, Consumer. J.M. Smucker sits in the same sector. Peters moved all three on the same day.
There are no vote-trade overlaps flagged in the data. The trades don't line up with a specific floor vote. What they line up with is a committee seat and a sector rotation. Those are different things. The reader gets to weigh how different.
The Alpha Record Is Not the Story You'd Tell at a Fundraiser
Peters's scored trading record across 9 evaluated positions: 5 positive, 4 negative, mean 30-day alpha of negative 3.4 percent versus the S&P 500. That's the full sample, not a cherry-picked run. He is, by this measure, a below-market trader.
The best trades in the record carry no committee overlap. A January 2026 purchase of Stanley Black and Decker generated 9.2 percent 30-day alpha. A same-day purchase of W.P. Carey returned 7.3 percent. A November 2025 purchase of Conagra Brands added 3.8 percent. None of those sit inside his committee jurisdictions.
The committee overlap trades, collectively, have not been kind. The Corteva sale from April 23 is sitting at negative 5.6 percent 30-day alpha. An Intel sale in December 2025, flagged for Technology overlap given his Commerce/Science manufacturing subcommittee, came in at negative 5.8 percent. The worst single trade in the record is an October 2025 sale of Organon at negative 39.9 percent alpha. No committee overlap on that one. Just a bad call.
The point is not that Peters has a secret edge. The point is that the trades with the most institutional reasoning behind them, the ones in sectors his committees actually touch, have underperformed the trades with no obvious connection to his day job. Make of that what you make of it.
Corteva Specifically
The Corteva sale earns a closer look because of what Corteva is and what the committee does.
Corteva Agriscience is one of the largest seed and crop protection companies in the United States. Its business is directly shaped by Farm Bill reauthorization, USDA funding allocations, pesticide regulation through the EPA and FDA, and trade policy affecting agricultural exports. The Senate Appropriations Agriculture subcommittee that Peters sits on funds the agencies that regulate Corteva's product lines and the programs that affect its customers' purchasing power.
Peters sold $15K-$50K of Corteva on April 23. The 30-day performance after that sale came in at negative 5.6 percent alpha, meaning the stock moved in a direction that made the sale look, at minimum, not wrong. That's not an accusation. The timing and the overlap are a fact pattern. The interpretation is the reader's job.
PepsiCo and the FDA Angle
The PepsiCo purchase is the other flagged trade. Peters bought $15K-$50K of PepsiCo on the same day he sold Corteva.
PepsiCo's regulatory exposure runs directly through the FDA, which the Agriculture, Rural Development, Food and Drug Administration subcommittee funds. That's the same subcommittee Peters sits on. The company has business interests in food labeling, sodium and sugar content regulation, and the broader FDA framework governing processed food.
The 30-day alpha on the PepsiCo purchase is 0.4 percent. That's essentially flat relative to the market. Not a winner, not a disaster. The data flags it for committee overlap and then the performance record shrugs.
Peters also picked up a small position in J.M. Smucker the same day. The Smucker disclosure is in the $1K-$15K range, which is a position small enough that it barely moves the needle financially but large enough to show up on a filing. No alpha score available on that one in the current dataset.
The Lame Duck and the Portfolio
A senator who isn't running again has a different set of incentives than one who needs to stand for re-election. Peters announced he's leaving. He's spending part of his remaining tenure working the Michigan Democratic primary by telephone and spending another part of it rotating his portfolio out of agricultural chemicals and into consumer food staples.
Members are required to disclose. They are not required to divest, recuse, abstain, or explain themselves to anyone. That's the rule. Yes, really.
The question of whether a lame-duck senator with Appropriations Agriculture jurisdiction should be trading in the sectors his subcommittee funds is one Congress has declined to answer definitively for thirty years. The STOCK Act requires the disclosure. It requires nothing else. Peters filed on time. The filings are sitting in the public record doing exactly what they're supposed to do.
The Broader Record
Nine scored trades. Five positive. Four negative. Mean alpha of negative 3.4 percent. The committee overlap trades are the ones that have moved against him most consistently, which is either an ironic coincidence or a data point about what happens when institutional knowledge meets actual markets.
Peters is not an outlier in the Senate. He's not running a hedge fund from a cloakroom. His disclosed position sizes are modest. But he's a senator on the Agriculture Appropriations subcommittee who sold a major agrochemical company and bought two consumer food companies on the same day, while simultaneously trying to shape who replaces him in a seat he's vacating.
The receipts are public. Make of them what you make of them.